Patents by Inventor Puay-Wah Phuan

Puay-Wah Phuan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CO-POTENTIATORS FOR THERAPY OF CYSTIC FIBROSIS CAUSED BY MINIMAL FUNCTION CFTR MUTANTS
    Publication number: 20220323425
    Abstract: Provided herein are combination-potentiator (“co-potentiator”) therapeutic regimens, which can be used to modulate cystic fibrosis transmembrane conductance regulator (CTFR) mutant proteins. Co-potentiators have potential utility for treatment of many loss-of-function mutations of the CFTR chloride channel (e.g., N1303K).
    Type: Application
    Filed: August 28, 2020
    Publication date: October 13, 2022
    Inventors: Alan S. VERKMAN, Puay-Wah PHUAN, Peter M. HAGGIE
  • Substituted 2-acylamino-cycloalkylthiophene-3-carboxylic acid arylamides as inhibitors of calcium-activated chloride channel TMEM16A
    Patent number: 11358947
    Abstract: Provided herein are inhibitors of transmembrane protein 16A (TMEM 16A), a Ca2+-activated CI? channel expressed widely in mammalian epithelia, as well as in vascular smooth muscle and some tumors and electrically excitable cells. TMEM16A inhibitors have potential utility for treatment or management of disorders of epithelial fluid and mucus secretion, hypertension, some cancers, pain, and other diseases.
    Type: Grant
    Filed: April 17, 2018
    Date of Patent: June 14, 2022
    Assignees: The Regents of the University of California
    Inventors: Marc O. Anderson, Alan S. Verkman, Puay Wah Phuan
  • SUBSTITUTED 2-ACYLAMINO-CYCLOALKYLTHIOPHENE-3-CARBOXYLIC ACID ARYLAMIDES AS INHIBITORS OF CALCIUM-ACTIVATED CHLORIDE CHANNEL TMEM16A
    Publication number: 20200123128
    Abstract: Provided herein are inhibitors of transmembrane protein 16A (TMEM 16A), a Ca2+-activated CI? channel expressed widely in mammalian epithelia, as well as in vascular smooth muscle and some tumors and electrically excitable cells. TMEM16A inhibitors have potential utility for treatment or management of disorders of epithelial fluid and mucus secretion, hypertension, some cancers, pain, and other diseases.
    Type: Application
    Filed: April 17, 2018
    Publication date: April 23, 2020
    Inventors: Marc O. ANDERSON, Alan S. VERKMAN, Puay Wah PHUAN
  • Cyanoquinoline compounds having activity in correcting mutant-CFTR processing and increasing ion transport and uses thereof
    Patent number: 9073863
    Abstract: The present disclosure provides pharmaceutical compositions, pharmaceutical preparations and methods for increasing activity of a mutant cystic fibrosis transmembrane conductance regulator protein (mutant-CFTR). The pharmaceutical compositions, pharmaceutical preparations and methods are useful for the study and treatment of disorders associated with mutant-CFTR, such as cystic fibrosis. The pharmaceutical compositions and pharmaceutical preparations may include one or more cyanoquinoline-containing compounds of the embodiments, or an analog or derivative thereof.
    Type: Grant
    Filed: May 25, 2012
    Date of Patent: July 7, 2015
    Assignee: The Regents of the University of California
    Inventors: Alan S. Verkman, Puay-Wah Phuan, Mark J. Kurth, John Knapp
  • Cyanoquinoline Compounds Having Activity in Correcting Mutant-Cftr Processing and Increasing Ion Transport and Uses Thereof
    Publication number: 20140296215
    Abstract: The present disclosure provides pharmaceutical compositions, pharmaceutical preparations and methods for increasing activity of a mutant cystic fibrosis transmembrane conductance regulator protein (mutant-CFTR). The pharmaceutical compositions, pharmaceutical preparations and methods are useful for the study and treatment of disorders associated with mutant-CFTR, such as cystic fibrosis. The pharmaceutical compositions and pharmaceutical preparations may include one or more cyanoquinoline-containing compounds of the embodiments, or an analog or derivative thereof.
    Type: Application
    Filed: May 25, 2012
    Publication date: October 2, 2014
    Applicant: The Regents of the University of California
    Inventors: Alan S. Verkman, Puay-Wah Phuan, Mark J. Kurth, John Knapp